Paragon Therapeutics
Paragon Therapeutics is dedicated to discovering and developing best-in-class biologics and complex biologics for patients with high unmet needs. Founded in 2021 by Fairmount, it leverages cutting-edge science and technology to identify and propel biologics to the clinic, with a focus on rapid development and transformative therapies across various disease areas.
Industries
Nr. of Employees
small (1-50)
Paragon Therapeutics
Waltham, Massachusetts, United States, North America
Patents
Services
End-to-end discovery and lead optimization for biologic candidates using protein and antibody engineering combined with high-throughput screening.
CMC planning and execution to generate clinical supply and data packages required for regulatory filings and first-in-human studies.
In-house drug metabolism and pharmacokinetics assessment to inform candidate selection and clinical dosing strategies.
Strategic portfolio management, alliance coordination, and licensing or spin-out enablement for assets discovered in-house.
End-to-end discovery and lead optimization for biologic candidates using protein and antibody engineering combined with high-throughput screening.
CMC planning and execution to generate clinical supply and data packages required for regulatory filings and first-in-human studies.
In-house drug metabolism and pharmacokinetics assessment to inform candidate selection and clinical dosing strategies.
Strategic portfolio management, alliance coordination, and licensing or spin-out enablement for assets discovered in-house.
Expertise Areas
- Biologics discovery and engineering
- Antibody therapeutic design and optimization
- CMC and GMP-readiness for biologics
- IND-enabling study execution
Key Technologies
- Protein engineering
- Antibody engineering
- High-throughput screening (HTS)
- CMC process development
News & Updates
Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2025 Financial Results.
Oruka Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update.
Spyre Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update.
Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2025 Financial Results.
Oruka Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update.
Spyre Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update.